Literature DB >> 18283453

18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?

Ruoh-Fang Yen1, Ke-Cheng Chen, Jang-Ming Lee, Yeun-Chung Chang, Jane Wang, Mei-Fang Cheng, Yen-Wen Wu, Yung-Chie Lee.   

Abstract

PURPOSE: This study was to compare (18)F-FDG positron emission tomography (PET) with thoracic contrast-enhanced CT (CECT) in the ability of lymph node (LN) staging non-small cell lung cancer (NSCLC) in a tuberculosis-prevalent country. The usefulness of dual time point PET imaging (DTPI) in NSCLC nodal staging was also evaluated.
METHODS: We reviewed 96 NSCLC patients (mean age, 65.3+/-11.7 years) who had received PET studies before their surgery. DTPI were performed on 37 patients (mean age, 64.8+/-12.2 years) who received an additional scan of thorax 3 h after tracer injection. The accuracies of nodal staging by CECT and PET were evaluated according to final histopathology of hilar and mediastinal LN resected by surgery.
RESULTS: The accuracy for nodal staging by CECT was 65.6% and that by PET was 82.3% (p<0.05). Six patients were over-staged and 11 were under-staged by PET. Tuberculosis (n=3, 50%) were mostly responsible for false-positive, while small tumor foci (n=7, 63.6%) were mostly accountable for false-negative. For the 37 patients with DTPI, 45 min standardized uptake value (SUV) and 3 h SUV for negative LNs are significantly lower than those for positive LNs (p<0.0001). Nevertheless, the retention index (RI) showed no significant difference between these two groups.
CONCLUSIONS: Our study demonstrates that PET is more accurate than CECT in LN staging NSCLC patients in Taiwan where TB is still prevalent. Semi-quantitative SUV method or DTPI with RI does not result in better diagnostic accuracy than visual analysis of PET images.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283453     DOI: 10.1007/s00259-008-0733-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

Review 1.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer.

Authors:  Ozcan Birim; A Pieter Kappetein; Theo Stijnen; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

2.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

3.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

Authors:  R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

4.  Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients.

Authors:  Kazuya Takamochi; Junji Yoshida; Koji Murakami; Seiji Niho; Genichiro Ishii; Mitsuyo Nishimura; Yutaka Nishiwaki; Kazuya Suzuki; Kanji Nagai
Journal:  Lung Cancer       Date:  2005-02       Impact factor: 5.705

5.  Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; Y Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

6.  How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study.

Authors:  Barbara M Fischer; Minna W B Olsen; Carsten D Ley; Thomas L Klausen; Jann Mortensen; Liselotte Højgaard; Paul E G Kristjansen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-13       Impact factor: 9.236

7.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

Authors:  J F Vansteenkiste; S G Stroobants; P R De Leyn; P J Dupont; J Bogaert; A Maes; G J Deneffe; K L Nackaerts; J A Verschakelen; T E Lerut; L A Mortelmans; M G Demedts
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

8.  Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.

Authors:  Jun Konishi; Koichi Yamazaki; Eriko Tsukamoto; Nagara Tamaki; Yuya Onodera; Toshiyuki Otake; Toshiaki Morikawa; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Respiration       Date:  2003 Sep-Oct       Impact factor: 3.580

9.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.

Authors:  Alexander Matthies; Marc Hickeson; Andrew Cuchiara; Abass Alavi
Journal:  J Nucl Med       Date:  2002-07       Impact factor: 10.057

10.  Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography.

Authors:  W J Scott; L S Gobar; J D Terry; N A Dewan; J J Sunderland
Journal:  J Thorac Cardiovasc Surg       Date:  1996-03       Impact factor: 5.209

View more
  21 in total

1.  Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosis-endemic region.

Authors:  Dae-Weung Kim; Chang Guhn Kim
Journal:  Jpn J Radiol       Date:  2011-10-19       Impact factor: 2.374

Review 2.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 3.  Ultrasound for intraoperative localization of lung nodules during thoracoscopic surgery.

Authors:  Yu-Han Huang; Ke-Cheng Chen; Jin-Shing Chen
Journal:  Ann Transl Med       Date:  2019-01

4.  Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.

Authors:  Jeong Won Lee; Seok-Ki Kim; Sang Mi Lee; Seung Hwan Moon; Tae-Sung Kim
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

5.  Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes.

Authors:  Sohyun Park; Jin Chul Paeng; Chang Hyun Kang; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-03       Impact factor: 9.236

6.  Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?

Authors:  Dae-Weung Kim; Woo Hyoung Kim; Chang Guhn Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-05

7.  Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease.

Authors:  Young-Sil An; Joo Sung Sun; Kyung Joo Park; Sung Chul Hwang; Kwang Joo Park; Seung Soo Sheen; Sungsoo Lee; Kyi Beom Lee; Joon-Kee Yoon
Journal:  Lung       Date:  2008-08-01       Impact factor: 2.584

8.  18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity.

Authors:  Jeong Won Lee; Bom Sahn Kim; Dong Soo Lee; June-Key Chung; Myung Chul Lee; Soonhag Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-09       Impact factor: 9.236

9.  (18)F-FDG PET/CT Findings in a Breast Cancer Patient with Concomitant Tuberculous Axillary Lymphadenitis.

Authors:  Jeong Won Lee; Sang Mi Lee; Jae Hyuck Choi
Journal:  Nucl Med Mol Imaging       Date:  2011-04-12

Review 10.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.